找回密碼
 To register

QQ登錄

只需一步,快速開始

掃一掃,訪問微社區(qū)

打印 上一主題 下一主題

Titlebook: Chronic Myeloid Leukemia; Rüdiger Hehlmann Book 20161st edition Springer International Publishing Switzerland 2016 Chronic myeloid leukaem

[復(fù)制鏈接]
樓主: Garfield
21#
發(fā)表于 2025-3-25 07:04:04 | 只看該作者
22#
發(fā)表于 2025-3-25 10:43:44 | 只看該作者
23#
發(fā)表于 2025-3-25 12:16:27 | 只看該作者
24#
發(fā)表于 2025-3-25 16:43:04 | 只看該作者
https://doi.org/10.1007/978-3-030-34898-4n has focused on the need to define and validate levels of deeper molecular response (MR) within the context of the IS. While there has been substantial progress, . measurement is technically challenging and standardization is an ongoing process.
25#
發(fā)表于 2025-3-25 22:12:24 | 只看該作者
Franz Breuer,Petra Muckel,Barbara Dierisbe recommended for patients with a well matched donor and low risk transplant profile as early as possible. It is discouraged for patients with failed response to multiple TKIs and no matched donor. Close interaction between CML physicians and transplant centers facilitates such a targeted risk adapted approach.
26#
發(fā)表于 2025-3-26 01:20:34 | 只看該作者
,Gütekriterien und ethische Fragen,ost importance even for drug companies. It should be considered the future criterion to evaluate the success of clinical trials, especially if we want to take into account quality of life of patients and also the economic aspect..The question of cure in CML is now one of the major concerns and has to be considered in the management of the disease.
27#
發(fā)表于 2025-3-26 04:29:39 | 只看該作者
Standardization of Molecular Monitoring for Chronic Myeloid Leukemia,n has focused on the need to define and validate levels of deeper molecular response (MR) within the context of the IS. While there has been substantial progress, . measurement is technically challenging and standardization is an ongoing process.
28#
發(fā)表于 2025-3-26 09:34:53 | 只看該作者
29#
發(fā)表于 2025-3-26 15:38:21 | 只看該作者
30#
發(fā)表于 2025-3-26 18:54:50 | 只看該作者
Response-Related Predictors of Survival in CML,h of treatment can be considered if unfavorable outcome has to be expected due to early response failure. Numerous studies have demonstrated the association of long-term outcome with early response for first-line treatment with imatinib, with second-generation TKI, and for second-line TKI treatment as well.
 關(guān)于派博傳思  派博傳思旗下網(wǎng)站  友情鏈接
派博傳思介紹 公司地理位置 論文服務(wù)流程 影響因子官網(wǎng) 吾愛論文網(wǎng) 大講堂 北京大學(xué) Oxford Uni. Harvard Uni.
發(fā)展歷史沿革 期刊點(diǎn)評(píng) 投稿經(jīng)驗(yàn)總結(jié) SCIENCEGARD IMPACTFACTOR 派博系數(shù) 清華大學(xué) Yale Uni. Stanford Uni.
QQ|Archiver|手機(jī)版|小黑屋| 派博傳思國際 ( 京公網(wǎng)安備110108008328) GMT+8, 2025-10-15 20:29
Copyright © 2001-2015 派博傳思   京公網(wǎng)安備110108008328 版權(quán)所有 All rights reserved
快速回復(fù) 返回頂部 返回列表
融水| 浮梁县| 石阡县| 永丰县| 将乐县| 比如县| 鸡西市| 杭锦后旗| 兰溪市| 新昌县| 开原市| 邯郸市| 玉树县| 汨罗市| 潼关县| 景宁| 隆安县| 翁牛特旗| 亚东县| 遂溪县| 安龙县| 故城县| 怀宁县| 鄂温| 全南县| 兖州市| 沐川县| 北京市| 宜宾市| 台北县| 台湾省| 合水县| 宜昌市| 高雄县| 金堂县| 佛坪县| 徐水县| 句容市| 许昌市| 绍兴县| 宁晋县|